Merck & Co., Inc. (MRK)
Rapid Micro Biosystems: Benefiting From Partnership With Merck; Initiating With 'Buy'
Initiating Rapid Micro Biosystems at 'buy' with $4.60 fair value, driven by strong growth potential in automated microbial quality control market. Growth Direct platform offers clear advantages over manual MQC, with automation, regulatory benefits, and a $10B addressable market opportunity. Merck partnership is a key catalyst, enabling global distribution, supply chain optimization, and improved gross margins for Rapid Micro Biosystems.
Merck (MRK) Falls More Steeply Than Broader Market: What Investors Need to Know
In the closing of the recent trading day, Merck (MRK) stood at $79.96, denoting a -1.91% move from the preceding trading day.
Merck & Co., Inc. (MRK) Presents at HIV Investor Event Transcript
Merck & Co., Inc. (NYSE:MRK ) HIV Investor Event July 17, 2025 9:00 AM ET Company Participants Chirfi Guindo - Senior VP & Chief Marketing Officer of Human Health Eliav Barr - Chief Medical Officer & Head of Global Clinical Development of Merck Research Laboratories Elizabeth Rhee - Corporate Participant Kathryn Hayward - Corporate Participant Peter Dannenbaum - Vice President of Investor Relations Conference Call Participants Alexandria Janet Hammond - Wolfe Research, LLC Asad Haider - Goldman Sachs Group, Inc., Research Division Courtney Breen - Sanford C. Bernstein & Co., LLC.
Why Merck Is A Better Dividend Stock Than Gilead Sciences
I reiterate my Hold rating on Merck & Co., Inc. and downgrade Gilead Sciences, Inc. to Sell, as MRK outperforms on dividend growth and valuation metrics. Compared to GILD, MRK features a longer dividend growth streak, a higher recent dividend increase, and a superior PEGY ratio. Both companies have similar payout ratios and mixed buyback histories, but GILD's inventory management is notably better than MRK's.
Brokers Suggest Investing in Merck (MRK): Read This Before Placing a Bet
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Merck (MRK) Falls More Steeply Than Broader Market: What Investors Need to Know
In the closing of the recent trading day, Merck (MRK) stood at $81.52, denoting a -2.57% move from the preceding trading day.
Merck Starts Phase III Studies on Once-Monthly Pill for HIV Prevention
MRK launches Phase III trials for its once-monthly HIV prevention pill MK-8527, aiming to rival Gilead's daily PrEP options.
MRK's Buyout Spree to Broaden Product Portfolio: Can it Aid Growth?
Merck's impending Verona buyout and recent biotech deals aim to expand its pipeline and cut reliance on Keytruda sales.
FDA Accepts Merck's Filing for Two-Drug, Once-Daily HIV Pill
MRK's regulatory filing for once-daily HIV pill DOR/ISL gets FDA acceptance, with a decision expected by April 2026.
Merck (MRK) Rises Higher Than Market: Key Facts
Merck (MRK) closed the most recent trading day at $83.71, moving +2.88% from the previous trading session.
Merck Faces Multiple Challenges: Will It Steer Through Successfully?
MRK banks on new launches as Keytruda faces a looming patent cliff and Gardasil weakens amid China's demand slump.
Merck dives into COPD treatments with $10 billion purchase of Verona Pharma
Verona Pharma's stock soars toward a record after $10 billion buyout deal with Merck.
